Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Abstract
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1–based medicines has spurred the development of new molecular entities and combinations with unique pharmacokinetic and pharmacodynamic profiles, exemplified by tirzepatide, a GIP-GLP-1 receptor coagonist. Simultaneously, investigational molecules such as maritide block the GIP and activate the GLP-1 receptor, whereas retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. Here I highlight evidence establishing the efficacy of GLP-1–based medicines, while discussing data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerns regarding pancreatitis have not been substantiated in large cardiovascular outcome trials (92, 93).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [92]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“Furthermore, long-term therapy is associated with nutritional deficiencies, lean mass loss, and frequent GI adverse events, including nausea, vomiting, diarrhea, and constipation, which may affect up to 70-85% of patients and lead to treatment discontinuation [22,38,41,60,61]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [41]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Self-citationEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Research works printed but not linked: 1
- Styrkarsdottir, Obesity variants in the GIPR gene do not associate with risk of fracture or bone mineral density, J Clin Endocrinol Metab
Cited by
Items 101–200 of 381
Chen, W., Qin, H., Zhou, Z., Chen, Y., Xu, X., Chen, Y., He, J., Xu, R., Gao, H., & Lu, Q. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.10.006 · Cited by 17
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8
“Furthermore, long-term therapy is associated with nutritional deficiencies, lean mass loss, and frequent GI adverse events, including nausea, vomiting, diarrhea, and constipation, which may affect up to 70–85% of patients and lead to treatment discontinuation [22,38,41,60,61].”
Narayan, N., Vadde, T., Sandesara, M. P., Divity, S., Mamytova, A., & Tagaev, T. (2025) · Cureus · doi:10.7759/cureus.77089 · Cited by 11
Alluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 11
Practical application of semaglutide: From evidence-based research to expert decisions
Салухов, В. В., Galstyan, G. R., Khalimov, Y. S., Бакулин, И. Г., Cherkashin, D. V., Shadrichev, F. E., & Sukhotskaia, N. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-185 · Cited by 8
Talavera, J. A., Teixeira, L., Klein, B., Lopes, R. R. D. S., Urina‐Jassir, D., Navalha, D. D. P., Bettinotti, B. G. M., Fernandez, N., Urina‐Triana, M., Welty, F. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70102 · Cited by 11
The effect of type 2 diabetes genetic predisposition on non-cardiovascular comorbidities
Arruda, A. L., Bocher, O., Taylor, H. J., Cammann, D., Yoshiji, S., Yin, X., Zhao, C. G., Chen, J., Wood, A. C., Ken, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64927-5 · Cited by 9
Zhu, D., Wang, W., Tong, G., Ma, J., WEN, B., Zheng, X., Shi, B., Shuguang, P., Wang, K., Shi, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68165-7 · Cited by 9
Li, M., Xu, S., Cai, H., Xiao, J., & Qin, Y. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156547 · Cited by 9
Noh, Y., Yin, H., Ghezala, I. B., Yu, O. H. Y., Suissa, S., & Azoulay, L. (2026) · Diabetes Care · doi:10.2337/dc25-2577 · Cited by 12
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
Lifestyle Modification in Prediabetes and Diabetes: A Large Population Analysis
Dansinger, M. L., Gleason, J. A., Maddalena, J., Asztalos, B. F., & Diffenderfer, M. R. (2025) · Nutrients · doi:10.3390/nu17081333 · Cited by 13
Gao, Z., Tabernacki, T., Dorney, I., Ding, P., Kaelber, D. C., & Xu, R. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02525-z · Cited by 10
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Wu, J., Perez, A., & Sullivan, P. W. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.10.1029 · Cited by 7
Nicholls, S. J., Ryan, D. H., Deanfield, J. E., Ferreira, D., Lang, C. C., Lincoff, A. M., Lingvay, I., Lübker, C., Terns, P. P., Rasmussen, S. M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.4824 · Cited by 10
Tamaki, N., Kimura, T., Wakabayashi, S., Yamazaki, T., Iwadare, T., Tanaka, N., & Kurosaki, M. (2026) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01930-2 · Cited by 11
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) enhance insulin secretion from pancreatic β-cells and sup - press appetite via central mechanisms, leading to improved glycemic control and reduced energy intake [88].”
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Ahmed, E. O., Gasmallah, S. I., Jalal, M., Mgbechidinma, C. L., & Ahmed, W. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100699 · Cited by 11
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review
CHENG, A. Y. Y., Heine, R. J., Prato, S. D., Green, J. B., Thieu, V. T., & Zeytinoglu, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16206 · Cited by 7
“85 For SGLT-2is, genital mycotic infections, volume depletion and diabetic ketoacidosis are established potential adverse effects.”
Kasagga, A., Assefa, A. K., Amin, M. N., Hashish, R., Tabari, K. A., Swami, S. S., & Nakasagga, K. (2025) · Cureus · doi:10.7759/cureus.85531 · Cited by 16
“While gastrointestinal adverse events remain the most common limiting factor to tolerability, the lack of an observed increase in serious adverse events or treatment-related mortality is consistent with the safety profiles reported in previous studies of incretin-based therapies [17].”
Yao, Y., Liu, N., Chen, S., Sun, M., & Guo, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03241-8 · Cited by 7
“…therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) [11], which are particularly compelling due to their multifactorial effects, which include improvements in glycemia, body weight, blood pressure, and dyslipidemia, alongside notable anti-inflammatory properties [12].”
Mashayekhi, Y., Asgari, A.-M., Pahlevan‐Fallahy, M., Karimi, M. A., Jalali, R., & Shaker, F. (2025) · Journal of orthopaedic surgery · doi:10.1177/10225536251391959 · Cited by 7
Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems
Shokr, H., Mekkawy, M. A., & Hindi, A. M. K. (2026) · Pharmaceuticals · doi:10.3390/ph19010136 · Cited by 10
“…more recent dual agonists such as tirzepatide, which simultaneously target both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, are widely prescribed across a broad spectrum of patients, including individuals seeking pharmacological support for metabolic optimization [4].”
Salama, L., & Sinn, L. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf053 · Cited by 9
Jones, T. L. Z., Kusmartseva, I., Litovsky, S. H., Thakar, R. G., Posgai, A. L., Eckel, R. H., & Atkinson, M. A. (2025) · Diabetes · doi:10.2337/db25-0017 · Cited by 15
A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide
Huang, M., Liu, G., Zhang, C., Wang, Y., Liu, S., & Zhao, J. L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1608657 · Cited by 12
“In some patients treated with GLP-1RA, the levels of circulating pancreatic enzymes increase, thereby having an important impact on the pancreas (Drucker, 2024).”
Singh, K., & Frishman, W. H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001045 · Cited by 5
Ponzo, V., Vitale, M., Bo, S., Broglio, F., Goitre, I., & Cioffi, I. (2025) · Nutrients · doi:10.3390/nu17213318 · Cited by 7
Tirzepatide-Induced Liver Injury: A Rare Complication
Spaeth, L. D., Jordan, K. M., Barlow, M., & Cottrell, D. A. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.11.009 · Cited by 5
Korus, S., Cembrowska-Lech, D., Kłoda, K., & Stachowska, E. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07702-4 · Cited by 8
“It is also unclear whether rapid loss of lean body mass (which is an independent risk factor for sarcopenia, gallstones, and recurrence of metabolic disorders) may increase the risk of regaining weight after discontinuation of the drug [21–25].”
Qian, P., Li, Y., Han, Y., Xu, C., Zou, P., Yang, F., Kang, X., Wu, M., Dong, J., Zou, Z., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.03.026 · Cited by 6
Ellegaard, A., Kårhus, M. L., Winther‐Jensen, M., Lund, A., & Knop, F. K. (2025) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000815 · Cited by 8
Lin, C., Chen, J., Meyerowitz‐Katz, G., Huang, Y., & Su, P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16191 · Cited by 5
Coupland, C., Sun, N., Khalil, A., Karaoglu, E., Liśkiewicz, A., Liśkiewicz, D., Grandl, G., Akindehin, S., Maity‐Kumar, G., Yang, B. S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102136 · Cited by 5
Friedman, O., & Tal, D. (2025) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2025.09.023 · Cited by 6
Frías, J. P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16593 · Cited by 6
López, G. P. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107122 · Cited by 5
Herges, J. R., Neumiller, J. J., & McCoy, R. G. (2025) · Clinical Diabetes · doi:10.2337/cd24-0115 · Cited by 5
Bank, N. C., Perle, S. J., Lauck, B. J., Rajesh, A. J., Jeffs, A. D., & Draeger, R. W. (2025) · Journal of Hand Surgery Global Online · doi:10.1016/j.jhsg.2025.100746 · Cited by 6
Ghazwani, M., & Hanı, U. (2025) · Scientific Reports · doi:10.1038/s41598-025-24911-x · Cited by 4
Do GLP-1 agonists affect perioperative risk in spine surgery? A systematic review and meta-analysis
Ononogbu-Uche, F. C., Toussaint, F. S., Saleh, A. W., Siddig, A. H. E., Ahmed, R., Akl, K., Algabri, M. H., Alwadai, M. M., Corliss, L. E., Foster, N. A., et al. (2025) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2025.100835 · Cited by 10
The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Accacha, S. D., Barillas, J., Gabriel, L., Srivastava, A., Gulkarov, S., Apsan, J., Leon, J. D., & Reiss, A. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010198 · Cited by 4
“The American Diabetes Association now includes GLP-1 receptor agonists in treatment algorithms for youth with type 2 diabetes, noting their safety and effectiveness for both glycemic control and weight loss [195].”
Achieving equitable access to incretin-based therapies in cardiovascular care
Reddy, T. K., Villavaso, C. D., Pulapaka, A. V., & Ferdinand, K. C. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100455 · Cited by 11
Mulcahy, J., DeLaRosby, A., & Norwood, T. (2025) · Physical Therapy · doi:10.1093/ptj/pzaf061 · Cited by 8
“19 Additional medication effects have been documented on other body systems such as the reproductive system, 21,22 renal system, 23,24 and psychological and cognitive systems, 25,26 immune system, 27 however, not all mechanisms are well understood.”
Uncovering the role of Gpr45 in obesity regulation
Karolczak, E. O., Li, C., Alcantara, I. C., Cohen, I. M., Gao, C., Xiao, C., Goldschmidt, A. I., Pinkus, C. A., Li, J., Li, M. M., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102174 · Cited by 9
Çetın, D., Bilgili, E. P., Komaç, Ö., Yetişken, M., & Güney, E. (2025) · Medicina · doi:10.3390/medicina61071152 · Cited by 10
“…cardiorenal benefits, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are increasingly preferred as effective treatments for obesity, have not demonstrated consistent evidence of disproportionate lean mass loss or reductions in muscle strength in body composition analyses [28].”
Neurobeachin ( NBEA ) is a novel gene associated with GLP ‐1 receptor agonist associated weight loss
Mariam, A., Breeyear, J. H., Daniels, N. J., Pantalone, K. M., Griebeler, M. L., Motsinger‐Reif, A. A., & Rotroff, D. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16612 · Cited by 4
“45 To address this potential source of confounding, we adjusted for T2D in our models and other T2D medications known to impact weight in the T2D-stratified analysis.”
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
“The largest fraction of the metabolic benefit is believed to be mainly achieved through the reduction of excess adiposity and improved glucose control, but a direct effect on inflammation may also be involved [3].”
The metabolic signature of salt intake: a cross-sectional analysis from the SCAPIS-study
Wuopio, J., Yi-Ting, L., Dekkers, K. F., Fall, T., Smith, J. G., Larsson, A., Engström, G., Orho‐Melander, M., Johnson, L., & Ärnlöv, J. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00997-y · Cited by 4
“The gut derived incretin Glucagon Like Peptide-1 (GLP-1), which has the ability to stimulate satiety, reduce food intake and has positive effects on cardiovascular health [43], has been shown to increase with low salt intake in salt-sensitive individuals [8, 44].”
GLP-1RAs: antidiabetic drug crossover—new hope for chronic inflammatory airway diseases
Chen, Y., Shen, Y., Shen, H., & Liu, Z. (2026) · Respiratory Research · doi:10.1186/s12931-026-03569-7 · Cited by 5
“The first clinically approved treatment for T2DM was exenatide, while dulaglutide, semaglutide, and tirzepatide are the most widely popular GLP-1RAs analogues today [15].”
Katsanos, C. S., Liu, Z., & Atherton, P. J. (2026) · Comprehensive physiology · doi:10.1002/cph4.70126 · Cited by 8
“Recently, interest in GLP-1 RAs has surged due to their transformative effects on body weight reduction (Drucker 2024; Aldawsari et al. 2023), fueling rapid growth in the field of obesity pharmacotherapy (Drucker 2024; Melson et al. 2024).”
Gut microbe–derived N -acyl serinol lipids shape host postprandial metabolic homeostasis
Dutta, S., Mahen, K. K., Massey, W. J., Varadharajan, V., Burrows, A. C., Horak, A. J., Mrdjen, M., Mouannes, N., Orabi, D., Osborn, L. J., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2517314123 · Cited by 6
“…incretin peptide that is predominantly secreted by the distal ileal and colonic L - cells following a meal and can exert diverse metabolic effects by enhancing insulin secretion, reducing food intake and delayed gastric emptying, and dampening stress - related and inflammatory pathways (37–40).”
A metabolic balance of GLP-1 and NMDA receptors in the brain
Yue, J. T. Y., Garrido, A. N., & Lam, T. K. T. (2024) · Cell · doi:10.1016/j.cell.2024.06.031 · Cited by 4
Manchanda, Y., Jones, B. J., Carrat, G., Ramchunder, Z., Marchetti, P., Leclerc, I., Thennati, R., BURADE, V. S., Natarajan, M., Shahi, P. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16652 · Cited by 5
Kong, M.-W., Yu, Y., Wan, Y., Gao, Y., & Zhang, C.-X. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i36.4036 · Cited by 4
Yousaf, T., Ahmad, I., Younas, Z., Hamdard, M. H., & Mashwani, Z. (2025) · ACS Omega · doi:10.1021/acsomega.5c01900 · Cited by 6
Car, M., Erceg, D., Udovičić, M., Bokun, T., & Rahelić, D. (2025) · Medicina · doi:10.3390/medicina61122210 · Cited by 4
“GLP-1 receptor agonists and, more recently, the dual GLP-1/GIP agonist have demonstrated robust glucose-lowering efficacy and cardiovascular benefits, leading to rapid global uptake [1,2].”
Kazi, M. A. I., Singh, S., & Haq, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248882 · Cited by 3
Zoubiri, H., Saiah, W., Otmane, A., Saidi, H., Makrelouf, M., Abderrahman, S. A., Haddam, A. E. M., & Koceir, E.-A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031218 · Cited by 3
“Pharmacological agents targeting in-cretins are currently recognized as new anti-diabetic therapeutic classes, such as liraglutide, semaglutide, and exanatide, and are used to treat in diabetes [26], including gestational diabetes [27], as well as MAFLD [28,29].”
The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults
Lunati, M. E., Cimino, V., Bernasconi, D. P., Romano, C., Disoteo, O., Rossi, A., Tinari, C., Fiorina, R. M., Gandolfi, A., Morpurgo, P. S., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag072 · Cited by 4
Hindi, A. M. K., Mekkawy, M. A., & Shokr, H. (2026) · Pharmaceuticals · doi:10.3390/ph19030365 · Cited by 6
“…such as lifestyle interventions or older pharmacotherapies, clinical data showed that patients using these injectables can lose up to 25.3% of their body weight compared to the 2–10% weight reduction typically achieved through conventional methods over the same period of time (68–72 weeks) [8–10].”
InfluentialGLP-1 receptor agonists in older people with type 2 diabetes: safety evidence from the real world
Marassi, M., & Fadini, G. P. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2640982 · Cited by 5
“The advent of oral semaglutide has removed these barriers [1], broadening access to the GLP-1RA class.”
InfluentialKaracabeyli, D., & Lacaille, D. V. (2026) · Rheumatology · doi:10.1093/rheumatology/keag147 · Cited by 4
“…of action such as dual agonists [e.g. tirzepatide, a co-agonist targeting glucose-dependent insulino-tropic polypeptide (GIP) and GLP-1 receptors], triple agonists (e.g. retatrutide, targeting glucagon, GIP and GLP-1 receptors) and combination therapies (e.g. cagrilintide–semaglutide) [25].”
Wang, H., Wang, W., Zhang, Y., Yao, J., Liu, Y., Pan, L., Wang, R., Wang, J., Xia, Z., Chen, L., et al. (2026) · Frontiers in Veterinary Science · doi:10.3389/fvets.2026.1797197 · Cited by 3
“These agents are currently used to treat type 2 diabetes and obesity in humans (128).”
Huang, Y., Tsou, M.-Y., Li, P., Chen, J.-C., Chen, S.-C., Hsieh, H., Meyerowitz‐Katz, G., Liu, Y., & Su, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70786 · Cited by 3
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), with semaglutide at the forefront, have revolutionised clinical approaches to adiposity reduction and blood glucose regulation in recent years [10, 11].”
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 4
Joshi, G. P. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005222 · Cited by 4
GD2TIF cells as a platform for single-dose and long-term delivery of biologics
Zhang, G., Yin, N., & Peng, M. (2025) · Nature Communications · doi:10.1038/s41467-025-63427-w · Cited by 3
Zheng, S., Yang, H., Zheng, J., Wang, Y., Jia, B., & Li, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312501 · Cited by 3
Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder
Oesterle, T., & Ho, M. (2025) · Brain Sciences · doi:10.3390/brainsci15070702 · Cited by 6
“Currently, GLP-1 receptor agonists are in clinical use for the treatment of type-2 diabetes and obesity [7,14].”
Novel Glucagon-like Peptide 1 Receptor Agonists for Treating Type II Diabetes
Sabnis, R. W. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00303 · Cited by 3
Rethinking Postpartum Glucose Assessment: Is One-Hour Testing the Key to Success?
Egan, A. M., & Dunne, F. (2025) · Diabetes Care · doi:10.2337/dci25-0021 · Cited by 4
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Muraoka, N., Jensen, M. B., Kartha, V. K., Carrico, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.26.678829 · Cited by 3
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Adverse effects and other aspects of drugs with incretin effect
Ballesteros-Pomar, M. D., & Lesmes, I. B. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107041 · Cited by 4
Glucagon-Like Peptide-1 Receptor Agonists and Youth Obesity
Edmondson, E. K., Shah, R. D., & Gregory, E. F. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.2077 · Cited by 2
Li, S., Chen, Y., Song, Z., Ou, P., Duan, Y., Liu, Q., & Wang, W. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05425-6 · Cited by 2
Effect of GLP ‐1 receptor agonists on idiopathic intracranial hypertension: A systematic review
de Oliveira, H. M., Ruelas, M. G., Fonseca, P. E. O., Diaz, C. A. V., de Paula, G. O., da Costa, P. R. F., Parker, T., & Kahle, K. T. (2025) · Headache The Journal of Head and Face Pain · doi:10.1111/head.70005 · Cited by 5
Matcha mitigates metabolic and inflammatory disturbances induced by high-fat-sucrose diets in rats
El-Aziz, N. M. A., Elbakatoshy, M. R., Farrage, E. A., Zannou, O., Tahergorabi, R., Khalifah, A. M., Aminzare, M., & Shehata, M. G. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.107112 · Cited by 5
Joshi, G. P. (2025) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007921 · Cited by 2
Balli, M. L. (2026) · Journal of Pharmacy Practice · doi:10.1177/08971900261416787 · Cited by 2
Bonga, K. N., & Padhan, M. (2026) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10565 · Cited by 2
Endogenous GIP signaling is indispensable for DPP ‐4 inhibitor‐mediated metabolic control in mice
Kubota‐Okamoto, S., Kubota, S., Tsuchida, H., Liu, Y., Banno, S., Imaizumi, T., Fujisawa, T., Takahashi, Y., Kato, T., Horikawa, Y., et al. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70252 · Cited by 2
L’hostellier, A., Kouanfack, C., Chazallon, C., Cardoso, S. W., Eholié, S. P., Banze, N., Halue, G., Capeau, J., Delaugerre, C., Moh, R., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-110560 · Cited by 2
“52 However, while these results are promising, their real-world application may be limited in the context of the ELDORADO trial, which includes countries in Latin America and sub-Saharan Africa, where access to GLP-1 receptor agonists remains extremely limited due to high costs and availability…”
Chen, Y., Lu, S., Li, C., Li, Y., Qin, C., He, Y., Niu, Y., & Sun, Q. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1814249 · Cited by 4
Lin, Y., Claflin, K. E., Aklan, İ., Morgan, D. A., Sullivan, A. I., Rudolph, M. C., Rahmouni, K., & Potthoff, M. J. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117093 · Cited by 3
“6,8,12 The mechanisms for this reduction in energy expenditure are unclear, but it is likely a compensatory response to maintain body weight.”
Desmond, L. W., & Lowry, C. A. (2026) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2026.100166 · Cited by 2
Almemari, S., Almulla, N., Alsarraf, Y., Badri, G., & Khan, N. S. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02273-3 · Cited by 4
“This profile is consistent with reports indicating that GLP-1 receptor agonists are more commonly prescribed among individuals with elevated metabolic and cardiovascular risk [23].”
Wachiraphansakul, N., Vongchaiudomchoke, T., Manosroi, W., Ruengorn, C., Noppakun, K., Ngamvichchukorn, T., Sood, M. M., Thavorn, K., Hutton, B., & Nochaiwong, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70884 · Cited by 2
Hu, H., Yin, H., Liu, Y.-W., Wang, Z., & Xie, H. (2026) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2026.101139 · Cited by 2
“GLP-1 receptor agonists (GLP-1 RAs), originally designed for the treatment of type 2 diabetes and obesity, have emerged as key candidates for the holistic management of obesity-driven OA by modulating the systemic metabolic environment [264].”
Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine
Romantsova, T. I. (2024) · Obesity and metabolism · doi:10.14341/omet13184 · Cited by 6
Sedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Gmehlin, C. G., Nemet, M., Rizwan, Z. M., Ahmad, S. R., Gajic, O., & Tekin, A. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001263 · Cited by 6
Effects of Weight-lowering Medications in People With Obesity and Rheumatic Diseases
Karacabeyli, D., & Lacaille, D. V. (2025) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-025-00232-y · Cited by 3
“…II trials are underway studying bimagrumab (a monoclonal antibody that blocks activin receptor II to induce fat loss while sparing lean mass), either alone or together with semaglutide or tirz-epatide, in people with elevated BMI (ClinicalTrials.gov, NCT05616013, NCT06643728 & NCT06901349) [ 94].”
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes · doi:10.2337/dbi24-0046 · Cited by 1
Yang, J., Zhang, C.-Z., Wang, J., & Zhang, J. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.103567 · Cited by 1
Grenet, G., Gougeon, A., Salzwedel, D. M., Jauca, C. D., & Wright, J. M. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016144 · Cited by 3
Miller, C. K., Young-Hyman, D. L., Wooldridge, J. S., Piatt, G., & Hawkins, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0020 · Cited by 1
Animal models for development of anti-obesity drugs in the age of GLP-1 agents
Culver, A. E., Stayrook, K. R., Comerota, M. M., Oblak, A. L., & Burris, T. P. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2507766 · Cited by 2
“These drugs are generally well-tolerated, with manageable gastrointestinal side effects, making them both effective and safe options for weight management and overall health improvement for many patients [2].”
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-06-06
- Volume
- 47
- Issue
- 11
- Pages
- 1873-1888
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4399395008
- Semantic Scholar
- 306e8b284bd34405b3e79c99c37f0dec0c95f1ed
- Cited by
- 383
- References
- 171
- Citations by year
- 2026: 176 · 2025: 168 · 2024: 39
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes for Health Research (154321)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, tirzepatide, retatrutide, survodutide, cardiorenal benefits, drug safety, fracture, bone mineral density, muscle strength, gastrointestinal motility, anesthesia, pancreatic diseases, biliary tract diseases, cancer risk, cardiometabolic disease, personalized medicine
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.